相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis
Nikki de Rouw et al.
CLINICAL PHARMACOKINETICS (2021)
Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment
Rene J. Boosman et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
Yukio Hosomi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Cumulative pemetrexed dose increases the risk of nephrotoxicity
N. de Rouw et al.
LUNG CANCER (2020)
Long-term exposure to pemetrexed induces chronic renal dysfunction in patients with advanced and recurrent non-squamous cell lung cancer: a retrospective study
Kengo Umehara et al.
RENAL REPLACEMENT THERAPY (2020)
Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial
Navneet Singh et al.
CANCER (2019)
Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis
N. de Rouw et al.
LUNG CANCER (2019)
Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study
S. Visser et al.
EUROPEAN JOURNAL OF CANCER (2019)
Safety of Same-Day Vitamin B12 Supplementation in Patients Receiving Pemetrexed for the Treatment of Non-Small-Cell Lung Cancer or Pleural Mesothelioma: A Retrospective Analysis
Zachary Schlei et al.
CLINICAL LUNG CANCER (2018)
Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Gary Middleton et al.
CURRENT MEDICAL RESEARCH AND OPINION (2018)
Dynamic change of fatigue of pemetrexed maintenance treatment in the JMEN trial
Li Zhang et al.
LUNG CANCER (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
D. Planchard et al.
ANNALS OF ONCOLOGY (2018)
Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study
Sabine Visser et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies
Corey J. Langer et al.
CLINICAL LUNG CANCER (2017)
Single-dose dexamethasone for the prevention of pemetrexed associated cutaneous adverse reactions
Raymond Elsoueidi et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
Management of febrile neutropaenia: ESMO Clinical Practice Guidelines
J. Klastersky et al.
ANNALS OF ONCOLOGY (2016)
Phase II study of oral vitamin B12 supplementation as an alternative to intramuscular injection for patients with non-small cell lung cancer undergoing pemetrexed therapy
Yusuke Takagi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Preventing and Managing Toxicities of High-Dose Methotrexate
Scott C. Howard et al.
ONCOLOGIST (2016)
Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
N. Girard et al.
ANNALS OF ONCOLOGY (2015)
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
J. Naidoo et al.
ANNALS OF ONCOLOGY (2015)
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
P. Baas et al.
ANNALS OF ONCOLOGY (2015)
Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids
Takumi Sakurada et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
Estimated Creatinine Clearance Rate Is Associated With the Treatment Effectiveness and Toxicity of Pemetrexed As Continuation Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Chung-Yu Chen et al.
CLINICAL LUNG CANCER (2015)
Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study
Cesare Gridelli et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
A Prospective Study of Shortened Vitamin Supplementation Prior to Cisplatin-Pemetrexed Therapy for Non-Small Cell Lung Cancer
Yusuke Takagi et al.
ONCOLOGIST (2014)
How Long Can Folinic Acid Rescue Be Delayed After High-Dose Methotrexate Without Toxicity?
Ian Joseph Cohen et al.
PEDIATRIC BLOOD & CANCER (2014)
Efficacy of Glucarpidase (Carboxypeptidase G2) in Patients with Acute Kidney Injury After High-Dose Methotrexate Therapy
Brigitte C. Widemann et al.
PHARMACOTHERAPY (2014)
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Onco-Nephrology: Renal Toxicities of Chemotherapeutic Agents
Mark A. Perazella
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
The Antifolates
Michele Visentin et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2012)
Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
Luis Paz-Ares et al.
LANCET ONCOLOGY (2012)
Toxic Epidermal Necrolysis and Antifolate Drugs in Cancer Chemotherapy
Claudine Pierard-Franchimont et al.
CURRENT DRUG SAFETY (2012)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Skin Toxicities Compromise Prolonged Pemetrexed Treatment
Belen Eguia et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Risk of Mortality in Patients With Cancer Who Experience Febrile Neutropenia
Gary H. Lyman et al.
CANCER (2010)
Therapeutics by Cytotoxic Metabolite Accumulation: Pemetrexed Causes ZMP Accumulation, AMPK Activation, and Mammalian Target of Rapamycin Inhibition
Alexandra C. Racanelli et al.
CANCER RESEARCH (2009)
Population Pharmacokinetic/Pharmacodynamic Analyses of Pemetrexed and Neutropenia: Effect of Vitamin Supplementation and Differences between Japanese and Western Patients
Jane E. Latz et al.
CLINICAL CANCER RESEARCH (2009)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer
Giorgio Vittorio Scagliotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
The proton-coupled folate transporter: Impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier
Rongbao Zhao et al.
MOLECULAR PHARMACOLOGY (2008)
Correlation of pemetrexed (PEM) NSCLC exposure-response relationships (ERRS) to clinical study results from western and Japanese patient populations
Jane Latz et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer
Chris H. Takimoto et al.
CLINICAL CANCER RESEARCH (2007)
Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications
Shrikanta Chattopadhyay et al.
MOLECULAR CANCER THERAPEUTICS (2007)
FMOE-MR: Content-driven multi-resolution MPEG-4 fine grained scalable layered video encoding
S. Chattopadhyay et al.
MULTIMEDIA COMPUTING AND NETWORKING 2007 (2007)
Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients
JE Latz et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy
JE Latz et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function
AC Mita et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy
V Caggiano et al.
CANCER (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Chemotherapy-induced neutropenia - Risks, consequences, and new directions for its management
J Crawford et al.
CANCER (2004)
Thymidine rescue: An antidote for pemetrexed-related toxicity in the setting of acute renal failure
M Castro
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Molecular, biochemical, and cellular pharmacology of pemetrexed
ID Goldman et al.
SEMINARS IN ONCOLOGY (2002)
Phase II trial of pemetrexed disodium (ALIMTA®, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer
SJ Clarke et al.
ANNALS OF ONCOLOGY (2002)
Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells
RB Zhao et al.
BIOCHEMICAL PHARMACOLOGY (2001)
The folate cycle and disease in humans
B Fowler
KIDNEY INTERNATIONAL (2001)
Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation
JD Roberts et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
分享论文
